

BRISTOL-MYERS SQUIBB COMPANY
WORLDWIDE REVENUES
QUARTERLY REVENUES TREND ANALYSIS
(Unaudited, dollars in millions)

	2019						2020						\$ Change		% Change			
	1st Qtr	2nd Qtr	6 Months	3rd Qtr	9 Months	4th Qtr ^(b)	Year ^(b)	1st Qtr ^(c)	2nd Qtr ^(c)	6 Months ^(c)	3rd Qtr ^(c)	9 Months ^(c)	4th Qtr ^(c)	Year ^(c)	Qtr vs. Qtr	YTD vs. YTD	Qtr vs. Qtr	YTD vs. YTD
Prioritized Brands																		
Revlimid	\$ —	\$ —	\$ —	\$ —	\$ —	\$ 1,299	\$ 1,299	\$ 2,915	\$ 2,884	\$ 5,799	\$ 3,027	\$ 8,826	\$ 3,280	\$ 12,106	\$ 1,981	\$ 10,807	**	**
Eliquis	1,925	2,042	3,967	1,928	5,895	2,034	7,929	2,641	2,163	4,804	2,095	6,899	2,269	9,168	235	1,239	12%	16%
Opdivo	1,801	1,823	3,624	1,817	5,441	1,763	7,204	1,766	1,653	3,419	1,780	5,199	1,793	6,992	30	(212)	2%	(3)%
Orencia	640	778	1,418	767	2,185	792	2,977	714	750	1,464	826	2,290	867	3,157	75	180	9%	6%
Pomalyst/Imnovid	—	—	—	—	—	322	322	713	745	1,458	777	2,235	835	3,070	513	2,748	**	**
Sprycel	459	544	1,003	558	1,561	549	2,110	521	511	1,032	544	1,576	564	2,140	15	30	3%	1%
Yervoy	384	367	751	353	1,104	385	1,489	396	369	765	446	1,211	471	1,682	86	193	22%	13%
Abraxane	—	—	—	—	—	166	166	300	308	608	342	950	297	1,247	131	1,081	79%	**
Empliciti	83	91	174	89	263	94	357	97	97	194	96	290	91	381	(3)	24	(3)%	7%
Reblozyl	—	—	—	—	—	—	—	8	55	63	96	159	115	274	115	274	N/A	N/A
Inrebic	—	—	—	—	—	5	5	12	15	27	13	40	15	55	10	50	**	**
Onureg	—	—	—	—	—	—	—	—	—	—	3	3	14	17	14	17	N/A	N/A
Zeposia	—	—	—	—	—	—	—	—	1	1	2	3	9	12	9	12	N/A	N/A
Established Brands																		
Vidaza	—	—	—	—	—	58	58	158	126	284	106	390	65	455	7	397	12%	**
Baraclude	141	147	288	145	433	122	555	122	121	243	100	343	104	447	(18)	(108)	(15)%	(19)%
Other Brands ^(a)	487	481	968	350	1,318	356	1,674	418	331	749	287	1,036	279	1,315	(77)	(359)	(22)%	(21)%
Total	\$ 5,920	\$ 6,273	\$ 12,193	\$ 6,007	\$ 18,200	\$ 7,945	\$ 26,145	\$ 10,781	\$ 10,129	\$ 20,910	\$ 10,540	\$ 31,450	\$ 11,068	\$ 42,518	\$ 3,123	\$ 16,373	39%	63%

** In excess of +/- 100%.

(a) Includes Sustiva, Reyataz, Daklinza and all other BMS and Celgene products acquired as part of the Celgene acquisition that have lost exclusivity in major markets, over-the-counter (OTC) brands and royalty revenue. Other Brands includes \$308 million and \$37 million relating to Celgene products for the years ended December 31, 2020 and 2019, respectively.

(b) Includes Celgene product revenues from November 20, 2019 through December 31, 2019.

(c) Includes Celgene product revenues for the entire period.